New drug combo tested to stop prostate cancer spread before surgery
NCT ID NCT01409200
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether adding the drug axitinib to standard hormone therapy before surgery helps men with prostate cancer that has spread to lymph nodes. About 73 men received either hormone therapy alone or hormone therapy plus axitinib before having their prostate removed. The goal was to see if the combination delays cancer recurrence after surgery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
hormone therapy (androgen deprivation therapy) and axitinib
What this could lead to
If successful, this could point toward a more effective pre-surgery treatment for prostate cancer that has spread to lymph nodes.
What could go wrong
This is a small, early-phase trial (73 people) with no results yet. Adding axitinib may not improve outcomes and could increase side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE III PROSTATE ADENOCARCINOMA AJCC V7 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States